CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Mike Nally

Chief Executive Officer, Generate:Biomedicines

Search every verified Mike Nally interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Mike Nally, chief executive officer of Generate: Biomedicines, discussed the company's work in generative biology and the application of artificial intelligence and machine learning to drug discovery and development in a March 2024 episode of The Business of Biotech podcast. He described the potential of these technologies to improve upon historical approaches, stating that early clinical programs suggest they may yield better answers than traditional methods. Nally also expressed frustration with the biopharmaceutical industry's declining research and development productivity over four decades, linking it to pricing practices, and argued that the industry's future lies at the intersection of science and technology. In the interview, Nally highlighted the vast search space for protein design, noting that the combinatorial possibilities of proteins are immense and that nature has only explored a small fraction of that space. He suggested that a technology capable of surveying this space could lead to significant discoveries. Nally also emphasized the value of a supportive ecosystem of peers in leadership roles, describing such networks as an asset that provides reassurance during uncertain periods.

Recent appearances

  • New Street Research, "AI Transforming Pharma" A conversation with Generate:Biomedicines

    July 07, 2025 · 📺 Generate:Biomedicines

    In a speaker series by New Street Research, “AI Transforming Industries” in partnership with March Capital, this series will explore how AI is fundamentally reshaping key business processes across industries, boosting productivity, altering competitive dynamics, and redefining how business is conducted. Conversations will provide insights into real-world deployments, including the intensity of AI use, and of course, the scale the compute infrastructure involved. Our first call is with Mike Nally, CEO of Generate:Biomedicines, a biotech innovator harnessing generative AI to rapidly design nove…

    Watch on YouTube ↗

  • Fireside Chat With Mike Nally And Jason Silvers From Generate:Biomedicines

    July 07, 2025 · 📺 ARK Funds

    Generate:Biomedicines is working on generative biology: a novel approach to drug development that allows the company to program protein-based modalities for the first time by bringing together machine learning, automated experimentation, and cutting-edge science, will change the way biotherapeutics are developed.  As of 6/30/2025 Generate:Biomedicines represents 1.12% of the ARK Venture Fund. To see the most updated holdings and other fund information, please visit https://www.ark-funds.com/funds/arkvx. Holdings subject to change.

    Watch on YouTube ↗

  • HumanX 2025, "AI in Drug Discovery: Pioneering a New Era of Medicine"

    March 21, 2025 · 📺 Generate:Biomedicines

    At HumanX 2025, the panel "AI in Drug Discovery: Pioneering a New Era of Medicine" brought together our CEO Mike Nally, CEO and Alex Zhavoronkov, founder and CEO of Insilico Medicine, to discuss how AI and generative models are reshaping drug discovery. The conversation explores programming biology with intent, expanding what’s druggable, and reducing development timelines—driving lasting impact on human health.

    Watch on YouTube ↗

  • Flagship Pioneering CEO Chat with Mike Nally at the 2025 J.P. Morgan Healthcare Conference

    January 17, 2025 · 📺 Generate:Biomedicines

    At the 2025 J.P. Morgan Healthcare Conference, Generate:Biomedicines CEO Mike Nally joins Christine Heenan of Flagship Pioneering for a CEO Chat on programming biology with generative AI. Mike discusses breakthroughs in CryoEM, data-driven experimentation, and how our multidisciplinary team is tackling challenges once thought impossible in therapeutic innovation.

    Watch on YouTube ↗

  • Mike Nally at the 2024 Montgomery Summit

    September 10, 2024 · 📺 Generate:Biomedicines

    Our CEO Mike Nally joins a distinguished panel at The Montgomery Summit to discuss the AI revolution in biopharma and the widespread adoption of machine learning to drive innovation in drug discovery and development. Watch the panel, featuring Jacob Berlin, PhD, CEO of Terray Therapeutics, and moderator D.A. Wallach, General Partner of Time BioVentures. #Biotechnology #Biotech #PatientFocusedDrugDevelopment #GenerativeAI #GenerativeBiology #AI #ML #DrugDiscovery #Innovation #ProgrammableBiology #Biology #Innovation #STEM #ClinicalTrials

    Watch on YouTube ↗

  • Mike Nally on Data in Biotech Podcast

    September 10, 2024 · 📺 Generate:Biomedicines

    Our CEO Michael Nally was featured on CorrDyn’s Data in Biotech podcast with Ross Katz, where he discussed how we are transforming drug development using Generative AI. Mike shares: "The phase 1 data for GB-0669 [a monoclonal antibody targeting the S2 stem helix in SARS-CoV-2] has shown a significant improvement in safety and efficacy, which paves the way for our next stages of development. Our approach leverages Generative Biology to design proteins that precisely target the intended conditions, thus reducing potential side effects and increasing therapeutic effectiveness." #Biotechnology…

    Watch on YouTube ↗

  • The AI Impact with Generate: Biomedicines' Mike Nally

    March 24, 2024 · 📺 Life Science Connect

    Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artificial intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate: Biomedicines, which bills itself at the "intersection of machine learning, biological engineering, and medicine." To get a grip on the "generative biology" work it's doing and the AI/ML impact it anticipates in the discovery and development of therapeutics, as well as clinical trials, we sat down with veteran biotech builder Mike Nally, CEO at Generate…

    Watch on YouTube ↗

  • 2024 CEO Chat: Mike Nally, CEO of Generate:Biomedicines

    January 11, 2024 · 📺 Flagship Pioneering

    Hear CEO of Generate:Biomedicines Mike Nally share updates on Generate and why the company may have the Mona Lisa of molecules when it comes to treating mild-to-moderate asthma. About Flagship Pioneering: Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Gen…

    Watch on YouTube ↗

  • Generate Biomedicines | XB 100 | Deep Tech with Bessemer Venture Partners

    June 14, 2023 · 📺 Bessemer Venture Partners

    Partner Andrew Hedin meets with CEO Michael Nally where they recount advancements in biotechnology and how leaders like Generate Biomedicines are working to help cure intractable diseases. Subscribe today and be the first to listen: https://bessemervp.team/subscribe Learn more about The XB100 The XB 100: https://www.bvp.com/xb100 The State of Deep Tech: https://www.bvp.com/atlas/state-of-de... About Bessemer Venture Partners — We help entrepreneurs lay strong foundations to build and forge long-standing companies. With more than 135 IPOs and 200 portfolio companies in the enterprise, con…

    Watch on YouTube ↗

  • 2023 Flagship CEO Chat: Mike Nally, CEO of Generate Biomedicines

    January 12, 2023 · 📺 Flagship Pioneering

    Mike Nally, CEO of Generate Biomedicines & Flagship Pioneering CEO-Partner, sits down with Christine Heenan, Chief Communications Officer & Executive Partner, Flagship Pioneering @ JPM 2023. For more on Generate Biomedicines, visit https://generatebiomedicines.com/. Website: www.flagshipioneering.com Twitter: @FlagshipPioneer Linkedin:   / flagship-pioneering  

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →